Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs
22 June 2017 - 9:00PM
Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative therapies for respiratory diseases,
today announces the appointment of Desiree Luthman, DDS to the
Company’s executive team as Vice President, Regulatory Affairs.
Dr. Luthman’s experience during the last two
decades includes a series of roles leading regulatory affairs teams
and strategies for pharmaceutical products spanning from early
development to post-approval marketing. Throughout her career, Dr.
Luthman has held regulatory positions at large global
pharmaceutical and biotechnology companies, including
Bristol-Meyers Squibb, Celgene and AstraZeneca. Prior to joining
Verona Pharma, Dr. Luthman directed regulatory activities related
to pulmonary disease at Sanofi and most recently led their
regulatory team through the FDA approval of dupilumab for atopic
dermatitis in the United States. Dr. Luthman earned her Doctor in
Dental Sciences from the Karolinska Institute in Sweden.
“We welcome Desiree to our growing Verona Pharma
team,” said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. “She
has an accomplished track record of working closely with the FDA
and EMA on behalf of international healthcare companies to achieve
key regulatory milestones. Her vast experience will be instrumental
as we advance our regulatory plans in the U.S. and Europe under her
leadership in our effort to deliver important new therapies to
patients with respiratory diseases.”
About Verona Pharma plc
Verona Pharma is a clinical-stage
biopharmaceutical company focused on developing and commercialising
innovative therapies for the treatment of respiratory diseases with
significant unmet medical needs.
Verona Pharma’s product candidate, RPL554, is a
first-in-class, inhaled, dual inhibitor of the enzymes
phosphodiesterase 3 and 4 that acts as both a bronchodilator and an
anti-inflammatory agent in a single compound. Verona Pharma is
developing RPL554 for the treatment of chronic obstructive
pulmonary disease (COPD) and cystic fibrosis (CF), and potentially
asthma.
Forward-Looking Statements
This press release contains forward-looking
statements. All statements contained in this press release that do
not relate to matters of historical fact should be considered
forward-looking statements.
These forward-looking statements are based on
management's current expectations. These statements are neither
promises nor guarantees, but involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from our expectations expressed or implied by the forward-looking
statements, including, but not limited to, statements regarding
advancing our regulatory plans in the U.S. and Europe and
delivering new therapies to patients with respiratory diseases.
These and other important factors under the
caption “Risk Factors” in our final prospectus filed with the
Securities and Exchange Commission (“SEC”) on April 28, 2017
relating to our Registration Statement on Form F-1, and our other
reports filed with the SEC, could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent management's estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change.
These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
For further information, please contact:
Verona Pharma plc |
|
Tel: +44 (0)20 3283
4200 |
Jan-Anders Karlsson,
Chief Executive Officer |
|
info@veronapharma.com |
|
|
|
FTI Consulting (UK
Media and Investor Enquiries) |
|
Tel: +44 (0)20 3727
1000 |
Simon Conway /
Stephanie Cuthbert / |
|
veronapharma@fticonsulting.com |
Natalie
Garland-Collins |
|
|
|
|
|
ICR, Inc. (US Media and
Investor Enquiries) |
|
|
Darcie Robinson |
|
Tel: +1 203 682
8379 |
|
|
Darcie.Robinson@icrinc.com |
Stephanie
Carrington |
|
Tel: +1 646 277
1282 |
|
|
Stephanie.Carrington@icrinc.com |
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024